See more : Feishang Anthracite Resources Limited (1738.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Altimmune, Inc. (ALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Altimmune, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chang-Ho Fibre Corporation (1468.TW) Income Statement Analysis – Financial Results
- Ukai Co.,Ltd. (7621.T) Income Statement Analysis – Financial Results
- Fortum Oyj (FORTUM.HE) Income Statement Analysis – Financial Results
- THINKINK PICTUREZ LIMITED (THINKINK.BO) Income Statement Analysis – Financial Results
- NRx Pharmaceuticals, Inc. (NRXPW) Income Statement Analysis – Financial Results
Altimmune, Inc. (ALT)
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 426.00K | -68.00K | 4.41M | 8.19M | 5.80M | 10.33M | 41.50K | 5.23M | 10.64M | 10.19M | 17.91M | 25.18M | 24.27M | 20.99M | 27.55M | 32.91M | 14.64M | 1.85M | 586.07K |
| Cost of Revenue | 477.00K | 68.00K | 551.30K | 33.51M | 17.07M | 18.46M | 18.41M | 7.22M | 5.06M | 4.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 115.00K |
| Gross Profit | -51.00K | -136.00K | 3.86M | -25.32M | -11.26M | -8.13M | -18.36M | -1.99M | 5.58M | 5.93M | 17.91M | 25.18M | 24.27M | 20.99M | 27.55M | 32.91M | 14.64M | 1.85M | 471.07K |
| Gross Profit Ratio | -11.97% | 200.00% | 87.50% | -309.40% | -194.16% | -78.68% | -44,249.39% | -38.07% | 52.41% | 58.15% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 80.38% |
| Research & Development | 65.80M | 70.54M | 74.54M | 49.77M | 17.77M | 18.46M | 18.41M | 4.84M | 5.13M | 9.32M | 15.29M | 19.51M | 21.22M | 20.88M | 30.22M | 31.81M | 16.56M | 0.00 | 0.00 |
| General & Administrative | 18.14M | 17.13M | 15.41M | 13.21M | 8.50M | 9.77M | 8.46M | 11.52M | 6.22M | 10.91M | 13.28M | 11.63M | 14.31M | 18.02M | 22.43M | 19.40M | 13.88M | 491.09K | 145.78K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.14M | 17.13M | 15.41M | 13.21M | 8.50M | 9.77M | 8.46M | 11.52M | 6.22M | 10.91M | 13.28M | 11.63M | 14.31M | 18.02M | 22.43M | 19.40M | 13.88M | 491.09K | 145.78K |
| Other Expenses | 12.42M | -32.00K | -373.87K | 24.15K | 15.14K | 277.89K | 5.67K | 7.85K | 8.14K | -762.00 | -6.07K | 47.86K | 461.07K | 5.66M | 872.30K | 813.89K | 705.37K | 153.29K | 0.00 |
| Operating Expenses | 96.36M | 87.67M | 89.95M | 62.98M | 26.27M | 28.22M | 16.17M | 16.49M | 11.50M | 20.38M | 28.75M | 31.44M | 35.99M | 44.55M | 53.52M | 52.02M | 31.15M | 644.38K | 145.78K |
| Cost & Expenses | 96.36M | 87.67M | 89.95M | 62.98M | 26.27M | 28.22M | 16.17M | 16.49M | 11.50M | 20.38M | 28.75M | 31.44M | 35.99M | 44.55M | 53.52M | 52.02M | 31.15M | 644.38K | 260.78K |
| Interest Income | 7.35M | 2.87M | 202.74K | 322.51K | 843.41K | 226.60K | 47.58K | 1.05K | 0.00 | 695.00M | 2.58K | 17.81K | 16.66K | 6.96K | 269.13K | 1.23M | 1.12M | 1.85M | 586.07K |
| Interest Expense | 35.00K | 8.00K | 5.66K | 9.42K | 2.24K | 297.09K | 162.14K | 168.15B | 54.58K | 210.40K | 369.28K | 342.56K | 54.57K | 5.94M | 2.84M | 2.57M | 2.12M | 0.00 | 0.00 |
| Depreciation & Amortization | 477.00K | 500.00K | 551.30K | 298.06K | 387.32K | 302.37K | 139.02K | 135.35K | 141.60K | 149.96K | 182.49K | 303.92K | 461.07K | 1.02M | 872.30K | 813.89K | 655.21K | 0.00 | 0.00 |
| EBITDA | -87.94M | -84.40M | -96.53M | -54.15M | -20.19M | -44.72M | -51.76M | -10.91M | -3.18M | -9.53M | -11.10M | -4.08M | -3.28M | -23.26M | -28.57M | -33.03M | -15.80M | -14.05M | 325.30K |
| EBITDA Ratio | -20,642.02% | 124,855.88% | -1,943.50% | -661.62% | -331.28% | -165.39% | -38,725.67% | -4,344.78% | 16.47% | -98.55% | -59.48% | -23.42% | -79.25% | -59.69% | -77.55% | -7.12% | -134.63% | 65.13% | 55.50% |
| Operating Income | -95.93M | -87.74M | -96.91M | -54.80M | -21.46M | -42.83M | -52.05M | -11.26M | -3.40M | -10.19M | -10.84M | -6.27M | -11.73M | -23.55M | -25.97M | -35.24M | -16.50M | 1.20M | 325.30K |
| Operating Income Ratio | -22,518.54% | 129,029.41% | -2,197.42% | -669.50% | -370.00% | -414.61% | -125,401.20% | -215.37% | -31.98% | -100.01% | -60.51% | -24.89% | -48.32% | -112.19% | -94.28% | -107.09% | -112.70% | 65.13% | 55.50% |
| Total Other Income/Expenses | 7.48M | 2.83M | -176.82K | 337.24K | 886.30K | -2.49M | -18.51K | 4.85K | 3.21M | 297.66K | -4.62M | -758.20K | 7.93M | -11.30M | -6.31M | -1.17M | 2.92M | 15.74M | 0.00 |
| Income Before Tax | -88.45M | -84.91M | -97.09M | -54.46M | -20.58M | -45.32M | -52.06M | 205.02M | -3.38M | -9.89M | -11.66M | -4.72M | -3,797.57B | -34,849.28B | -32.28B | -36.42B | -13.59M | 1.20M | 325.30K |
| Income Before Tax Ratio | -20,762.21% | 124,867.65% | -2,201.43% | -665.38% | -354.72% | -438.68% | -125,445.79% | 3,920.00% | -31.76% | -97.09% | -65.07% | -18.77% | -15,649,592.52% | -165,999,488.89% | -117,168.01% | -110,646.14% | -92.79% | 65.13% | 55.50% |
| Income Tax Expense | 0.00 | -197.00K | -919.51K | -5.42M | -58.50K | -6.15M | -5.64M | 11.17M | 61.75K | 61.75K | 61.75K | 195.53K | -7.93M | 15.93M | 6.31M | 17.30M | -2.87M | 187.00K | 48.00K |
| Net Income | -88.45M | -84.71M | -96.17M | -49.04M | -20.52M | -39.17M | -46.43M | 193.85M | -3.44M | -9.96M | -11.72M | -4.92M | -3.80M | -34.85M | -32.28M | -36.42M | -13.59M | 1.02M | 277.30K |
| Net Income Ratio | -20,762.21% | 124,577.94% | -2,180.58% | -599.20% | -353.71% | -379.16% | -111,860.32% | 3,706.44% | -32.34% | -97.70% | -65.42% | -19.54% | -15.65% | -166.00% | -117.17% | -110.65% | -92.79% | 55.01% | 47.31% |
| EPS | -1.66 | -1.81 | -2.33 | -1.91 | -1.56 | -13.98 | -108.77 | -49.80 | -16.13 | -51.91 | -69.40 | -30.55 | -24.07 | -323.59 | -351.19 | -476.15 | -431.69 | -11.48K | 12.00 |
| EPS Diluted | -1.66 | -1.81 | -2.33 | -1.91 | -1.56 | -13.98 | -108.77 | -49.80 | -16.13 | -51.91 | -69.40 | -30.55 | -24.07 | -323.59 | -351.19 | -476.15 | -431.69 | -11.48K | 9.00 |
| Weighted Avg Shares Out | 53.25M | 46.93M | 41.28M | 25.64M | 13.12M | 2.80M | 426.83K | 230.38K | 213.28K | 191.78K | 168.86K | 161.08K | 157.77K | 107.70K | 91.92K | 76.48K | 31.48K | 1.89K | 26.23K |
| Weighted Avg Shares Out (Dil) | 53.25M | 46.93M | 41.28M | 25.64M | 13.12M | 2.80M | 426.83K | 230.38K | 213.28K | 191.78K | 168.86K | 161.08K | 157.77K | 107.70K | 91.92K | 76.48K | 31.48K | 1.89K | 27.74K |
Altimmune CEO on what's next for its experimental obesity drug
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, potential commercial partnership and more.
Altimmune Stock Up More Than 25% in a Month: Here's Why
ALT's recent progress related to the development of the lead product candidate, pemvidutide, for treating obesity and MASH is aiding the stock.
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids
Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge
Results from the phase 2b IMPACT study, using Pemvidutide for the treatment of patients with MASH, expected Q2 of 2025. The global metabolic dysfunction-associated steatohepatitis market size is expected to reach $7.64 billion by 2031. Successful EOP2 meeting with FDA,...
Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health
Altimmune, Inc.'s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for obesity demonstrated significant weight loss and lean mass preservation, with up to 15.6%...
ALT5 Sigma Reports Fiscal Financial Results for Third Quarter 2024
Record quarter for ALT5 with Q3 revenue of $4.94 million New customer onboarding strong in Q3 and continuing into Q4 Launching additional capabilities for Alt5 Prime and Alt5 Pay in Q4 2024 and Q1 2025 LAS VEGAS, NV / ACCESSWIRE...
Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan, Investor Relations Advisors, Altimmune Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Andrew Shutterly...
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of Directors granted equity awards under Altimmune's 2018 Inducement Grant Plan, as a material inducement...
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), effective immediately. Mr. Weaver will lead the Company's finance and accounting functions,...
Source: https://incomestatements.info
Category: Stock Reports